Lior Shamai, DO
Interventional Cardiology · Tulsa, OKNPI 1093963563
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Medtronic at 29.0% of the total.
Across 219 payments — averaging $54.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$2K
- Medicure Pharma Inc.$900
- Abiomed$854
- Bayer$650
- Davol Inc.$544
- plus $4K from 29 others
What the payments were for
- Consulting fees$3,44329%
- Speaking & faculty fees$5975%
- Travel & lodging$9528%
- Food & beverage$6,77457%
- Education$1401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 29 | $3,457 |
| Abbott | 63 | $1,910 |
| Medicure Pharma Inc. | 2 | $900 |
| Abiomed | 16 | $854 |
| Bayer | 4 | $650 |
| Davol Inc. | 1 | $544 |
| Amgen | 13 | $540 |
| BD | 1 | $455 |
| Novartis | 22 | $359 |
| Inari Medical, Inc. | 2 | $286 |
| Boston Scientific | 4 | $274 |
| Boehringer Ingelheim | 2 | $212 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $203 |
| Penumbra, Inc. | 1 | $140 |
| Amarin Pharma, Inc. | 22 | $138 |
| Actelion Pharmaceuticals US, Inc. | 2 | $115 |
| United Therapeutics Corporation | 1 | $100 |
| Jazz Pharmaceuticals Inc. | 1 | $93 |
| Cardiovascular Systems Inc. | 3 | $87 |
| Pfizer | 2 | $86 |
| Chiesi USA, Inc. | 1 | $76 |
| Regeneron | 1 | $59 |
| Lantheus Medical Imaging, Inc. | 1 | $50 |
| Kestra Medical Technology Services, Inc. | 3 | $48 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $42 |
| Merck | 2 | $40 |
| Irhythm Technologies, Inc. | 2 | $32 |
| Edwards Lifesciences | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Atricure, Inc. | 1 | $20 |
| Cardinal Health 200 LLC | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Biosense Webster, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,493
- Aggrastat (tirofiban HCl)$600
- Impella$559
- Adempas$525
- FLOWTRIEVER CATHETER, S$447
- Acute cardiovascular care$300
- TrailBlazer$210
- AURORA EV-ICD MRI SURESCAN$147
- Indigo System$140
- Kerendia$125
- EKOSONIC$125
- JARDIANCE$124
- CROSSBOSS$114
- Confirm Rx$111
- Repatha$107
- Optis Coronary Imaging System$103
How this compares
$11,906 in reported general payments places this provider in the 65th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $90,166 |
| BrilintaTicagrelor | 46 | $23,220 |
| FarxigaDapagliflozin Propanediol | 28 | $21,226 |
| XareltoRivaroxaban | 21 | $17,829 |
| OzempicSemaglutide | 12 | $13,667 |
| JardianceEmpagliflozin | 30 | $13,246 |
| EntrestoSacubitril/Valsartan | 14 | $12,787 |
| VascepaIcosapent Ethyl | 21 | $11,333 |
| Repatha SyringeEvolocumab | 19 | $11,133 |
| MultaqDronedarone Hcl | 14 | $11,043 |
| Repatha PushtronexEvolocumab | 14 | $8,252 |
| Atorvastatin Calcium | 189 | $2,908 |
| Icosapent Ethyl | 12 | $2,612 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 213 | $2,296 |
| Valsartan | 45 | $2,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $86 | $90,166140 claims |
| Johnson & JohnsonXarelto | $14 | $17,82921 claims |
| Novo NordiskOzempic | $14 | $13,66712 claims |
| Boehringer IngelheimJardiance | $212 | $13,24630 claims |
| NovartisEntresto | $359 | $12,78714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Stewart KatzTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.